Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML - Drug Trials For Money - Paid Clinical Trials

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Condition:   Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions:   Drug: Gilteritinib;   Drug: Vyxeos
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Jazz Pharmaceuticals
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 28, 2021 / by / in
Comments